Advice
in the absence of a submission from the holder of the marketing authorisation:
pasireotide (Signifor®) is not recommended for use within NHS Scotland.
Indication under review: treatment of adult patients with Cushing’s disease for whom surgery is not an option or for whom surgery has failed.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice87KB (PDF)
Medicine details
- Medicine name:
- pasireotide (Signifor)
- SMC ID:
- 815/12
- Indication:
- treatment of adult patients with Cushing' s disease for whom surgery is not an option or for whom surgery has failed.
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Endocrine system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 08 October 2012